Muc-1 α-gal epitope (HyperAcute®) NCT00569387 Active, not recruiting II Muc-1 α-gal epitope (HyperAcute®) NCT00614601 Active, not recruiting II Muc-1 α-gal epitope (HyperAcute®) NCT01072981 ...
The study by Ma et al. provides fundamental findings and compelling evidence that Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (PERSIST): A ...
Therefore, the extracted platelets were subjected to a complement hemolysis assay (Figure 2). It was shown that a large number of platelets from the patient were destroyed after the addition of ...
Longitudinal characteristics of heavy and light chain clonal families.
The addition of HER2-targeted antibodies (i.e., trastuzumab, pertuzumab ... activating FcγR results in antibody-dependent cellular cytotoxicity and phagocytosis (ADCC and ADCP). With the exception of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback